Welcome to the website of the
Angiogenesis Laboratory Amsterdam
Angiogenesis is a key process in cancer. It is therefore a target in the development of novel anti-cancer therapies. The Angiogenesis Laboratory Amsterdam seeks to unravel the fundamental processes and mechanisms underlying angiogenesis and vascular development. The major aim is to use new knowledge and technology for the development of new treatment modalities in the clinic.
June 2018 – The Dutch Cancer Society (KWF) decided to fund the Angiogenesis Laboratory’s cancer vaccination program. The KWF press release can be found here.
The VUmc Master Oncology and OOA BioBusiness course will be held October 29th – November 9th. For more information please visit: http://www.ooa-graduateschool.org/biobusiness/
Recent research of the Angiogenesis Laboratory
A new technology for cancer vaccination against self-antigens. Huibers et al, Vaccine, 2018
A cancer vaccine against VEGF. Wentink et al. PNAS 2016
Rapid identification of optimal drug combinations. Nowak-Sliwinska 2016 Nature Protoc
PAI-1 involvment in angiogenesis. Bajou et al. Nature Med. 2014.
Key original research papers of the Angiogenesis Laboratory
Rapid onset of angiogenesis after angiostatic drug discontinuation. Griffioen et al. Clin. Cancer res. 2012
Galectin-1 is an angiogenic growth factor. Thijssen et al. Cancer Res. 2010
IL-21 is an angiogenesis inhibitor. Castermans et al. Blood 2008
Isolation of tumor endothelial cells. Van Beijnum et al. Nature Protoc 2008
Quantum dot-based imaging of angiogenesis. Mulder et al. Nano Letters 2006
Novel targets in the tumor vasculature. Van Beijnum et al. Blood 2006
Galectin-1 a key molecule in angiogenesis, Thijssen et al. PNAS 2006
Review papers of the Angiogenesis Laboratory
Role of the tumor stroma in resistance against angiostatics. Huijbers et al. Drug Resist. Update, 2016
The great escape; resistance to antiangiogenic therapy. Van Beijnum et al. Pharm Rev. 2015
Vaccination against the tumor vasculature. BBA Cancer 2015